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INTRODUCTION
Epilepsy is a common neurological condition, with
a lifetime prevalence of between 2%1, 2 and 5%3 of
the general population, and a point prevalence of be-
tween 4 and 80 per 10004. So common is it among
all races that epilepsy may be viewed, not as a rare
curse on the individual, but as an all-too frequent price
that man and other vertebrates pay for maintaining a
plastic and adaptable central nervous system. Within
the first few years of the next century, some estimates
suggest that there will have been 11 new antiepilep-
tic drugs (AEDs) licensed for use as either add-on or
monotherapy since the late 1980s5. Despite these re-
cent welcome additions to the ranks of available an-
ticonvulsants6 epilepsy remains both stigmatizing and
debilitating for many of those with the disorder7. Are
there grounds for optimism about the possibility of
treating refractory epilepsy?
Previous studies have shown that around one-third
of patients will remain refractory to anticonvulsant
monotherapy with the established drugs7, 8. Given this,
the new drugs have, with justification, generated a
great deal of interest, but despite their use most clin-
icians would admit that a significant number of pa-
tients with epilepsy have seizures that remain unsat-
isfactorily controlled9. The challenge for epileptolo-
gists over the coming decades is to further reduce the
size of this population with refractory disease. The
new generation of AEDs are undoubtedly an advance
in the treatment of epilepsy (given their advantages
of increased tolerability6, 10 and a decreased tendency
to cause pharmacokinetic interactions11), but it could
be argued that a continued search for more new an-
ticonvulsants is an inefficient way of helping our pa-
tients. Perhaps it would be more fruitful to look for
better ways of using the drugs already at our dis-
posal.
For many different conditions in many different spe-
cialties, the use of drug combinations is the rule rather
than the exception. Admittedly, anticonvulsants are
potentially neurotoxic8, can result in severe systemic
reactions4, and have the tendency to sustain multi-
ple pharmacodynamic and pharmacokinetic interac-
tions12. The same, however, is true of antiparkinsonian
drugs13, and monotherapy would never be advocated
as the ideal management strategy for the treatment of
Parkinson’s disease13. In fact here the opposite philos-
ophy applies, where a rational combination of com-
pounds is used at an early stage in an attempt to delay
symptomatic progression13.
Since the 1970s, in contrast, anticonvulsant
monotherapy has long been regarded as the ideal man-
agement strategy. A series of studies by Shorvon and
Reynolds14–16 argued against AED polypharmacy on
the basis of its strong association with adverse events,
they felt, with little evidence of an increase in effi-
cacy. While it seems axiomatic that newly diagnosed
epilepsy should be treated with a single drug, the di-
dacticism in favour of monotherapy fails to recog-
nize the realities of everyday practice. One survey has
shown17 that even when under review by specialist
epilepsy services, almost half the patients required
(or, at least, were receiving) long-term treatment with
anticonvulsant polypharmacy. At present, even taking
into account those compounds currently undergoing
phase three testing, it seems unlikely that any of the
new AEDs will, by themselves, prove to be the ‘magic
bullet’ for epilepsy. In a medical climate so keen on ev-
idence guiding our medical management, it therefore
falls to us as epilepsy specialists to formulate a rational
strategy for its treatment. Sadly, though, it seems pre-
†
This was one of the winning entries in the young physician section of the Millenium Gower Prize Competition 1999.
1059–1311/00/030170 + 09 $35.00/0 c© 2000 BEA Trading Ltd
Antiepileptic drugs: safety in numbers? 171
mature to be postulating which AED polypharmacy is
best when we still have not fully addressed the issue
of whether polypharmacy is superior to monotherapy
in the treatment of refractory epilepsy.
THE CASE FOR ANTICONVULSANT
MONOTHERAPY
The success of AED monotherapy will be enhanced
when the drugs are used most appropriately: to state
the obvious, each patient should be started on the
right drug for their epilepsy at the right dosage. A
proper clinical history, with relevant investigations
should ensure that patients with a primary generalized
epilepsy18 (e.g. juvenile myoclonic epilepsy18 or ab-
sence seizures18) or benign focal epilepsies of child-
hood19 receive appropriate initial treatment. Impor-
tantly, for example, absence and myoclonic seizures
can be exacerbated by carbamazepine20, 21 or vigaba-
trin20, 21, so in these circumstances syndromic classifi-
cation of epilepsy becomes most important, indicating
the drugs most likely to protect against all potential
seizure types in addition to those which have already
revealed themselves.
Careful assessment by an experienced epileptologist
may allow such a syndromic diagnosis to be made,
which can influence the choice of drug, or even in-
dicate that anticonvulsant monotherapy is less likely
to be completely successful22. Phenobarbitone, pheny-
toin, carbamazepine and valproic acid have shown
similar efficacy when used as monotherapy8, 23 in pa-
tients with newly diagnosed epilepsy. Some of the
newer drugs have been compared with their older
counterparts under trial conditions, but many of the
key comparisons are still awaited. How good are the
new AEDs when they are compared directly with their
older counterparts? Brodie et al.10 suggested that lam-
otrigine was as efficacious as carbamazepine, while
being significantly better tolerated. Two further stud-
ies comparing lamotrigine with phenytoin24 and car-
bamazepine25, however, failed to differentiate them in
terms of either efficacy or effectiveness. There remains
a need for comparative monotherapy studies of val-
proate versus lamotrigine.
Topiramate has also been assessed as monother-
apy26, but only in comparison with an ‘active placebo’
(a subtherapeutic dose of topiramate). In a study by
Kalvainen27, monotherapy with vigabatrin was bet-
ter tolerated than with carbamazepine, while lacking
its efficacy. Based on the available evidence, the new
AEDs are no more efficacious than their older counter-
parts, so how can our chances of therapeutic success
be maximized?
Given the incessant calls for ‘evidence’ to guide fu-
ture practice, we should bear in mind that much of
our ‘knowledge’ of AED monotherapy is taken for
granted. The superior efficacy of sodium valproate and
ethosuximide over phenytoin and carbamazepine in
the absence of seizures seems too obvious to demand
confirmation in a prospective clinical study, but there
are no data differentiating the efficacies of sodium val-
proate and ethosuximide in the absence of epilepsy28.
Similarly, while no one would argue that for most pa-
tients with juvenile myoclonic epilepsy, sodium val-
proate is the drug of choice29, no major differences
in efficacy between carbamazepine, phenytoin, barbi-
turates, and sodium valproate in the treatment of par-
tial epilepsies have been fully established8, 23, 30, in the
face of conventional practice in many epilepsy clinics.
The limited role for barbiturate drugs is supported in
the study by Mattson et al.8, where they were shown
to be less well tolerated than phenytoin and carba-
mazepine.
How should we deal with cases where monotherapy
fails to give complete seizure control? Firstly the wide
interindividual variation in optimal doses of anticon-
vulsants31 should be borne in mind: one study32 has
shown that increasing the dosage of current therapy
to maximally tolerated levels can bring seizure con-
trol in almost one-third of patients considered to have
seizures ‘refractory’ to monotherapy with phenytoin
or primidone. Adverse events may be minimized dur-
ing dosage escalation by avoiding over-rapid dosage
titration or by using controlled-release formulations,
particularly with carbamazepine33, 34 and less con-
vincingly with valproic acid35.
Even when the first monotherapy fails, it need not
necessarily follow that polypharmacy is an inevitable
requirement. Hakkareinen36 investigated the success
rate of monotherapy with either carbamazepine or
phenytoin when the other had failed, and found that
one-third of the treatment failures were successfully
controlled by monotherapy with the alternative drug.
Similarly, Mattson et al.8 found that 46% of those un-
successfully treated with an initial monotherapy re-
sponded to an alternative monotherapy. In this study,
however, some patients were originally treated with
phenobarbital or primidone, neither of which would
he today accept as reasonable first-line monotherapy.
Anticonvulsant monotherapy will be adequate for
most patients with newly diagnosed epilepsy, and
it is of paramount importance that the chances of
monotherapy succeeding are maximized. Even if the
first drug fails at maximally tolerated dosages, how-
ever, a second monotherapy may well prove to be ef-
fective in a substantial minority of patients. In sum-
mary, however, although AED monotherapy is good,
it is still not good enough.
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THE CASE FOR AED POLYPHARMACY
Notwithstanding the poor image of polypharmacy,
monotherapy will fail in a significant proportion
of patients, necessitating a trial of polypharmacy
with anticonvulsants. Despite the observations of
Hakkareinen36 and Mattson8, we have no randomized
trials comparing alternative monotherapy with add-on
therapy in groups of patients with poorly controlled
epilepsy. In the study by Mattson et al.8, 39% of
monotherapy ‘non-responders’ were helped by the ad-
dition of a second drug, with 17% becoming seizure-
free. A trial of adjuvant valproic acid in cases where
carbamazepine had failed as monotherapy, demon-
strated ‘improvement’ in a similar number of patients
while on combination therapy, with 17% becoming
seizure-free37. Certainly there is an abundance of trials
to prove the superiority of the new antiepileptic drugs
over placebo in refractory epilepsy38, although there
would be some grounds for doubting whether all of
the trial subjects were previously optimally treated!
Despite its efficacy, polypharmacy has long been
thought to be fraught with disadvantages: it is held to
be responsible for an increased frequency of adverse
events17, pharmacokinetic interactions12, and terato-
genesis39, while conferring only limited improve-
ments in seizure control16. In one study40, monother-
apy with phenytoin or carbamazepine produced ad-
verse effects in 28 and 38% of patients respectively,
while their combination produced adverse events in
around three-quarters of all patients. However, Lam-
mers et al.41, following a retrospective review, were of
the opinion that it was dosage rather than the number
of anticonvulsants used that determined the frequency
and severity of adverse events.
As an ‘irreversible’ adverse event, teratogenicity
must bear specific examination. Even as monother-
apy, AEDs42, 43 seem to increase the risk of major
fetal malformation by a factor of around five43: the
most common AED-related malformations are hare-
lip, cleft palate and cardiovascular anomalies. Such
data should be enough to ensure that AED therapy is
only begun after careful consideration. Estimates sug-
gest the malformation risk to be 1–2% of pregnan-
cies on AEDs28. Early screening with fetal ultrasound,
serum alpha-fetoprotein and, where indicated, amnio-
centesis should be offered to women becoming preg-
nant while on AEDs.
There are good reasons why polypharmacy with
older anticonvulsants should not be universally suc-
cessful. Each has a wide range of actions44, while
their anticonvulsant efficacy relies, at least in part,
on sodium channel blockade44. Random combina-
tion of these widely active drugs might reasonably be
thought to merely increase the degree of sodium chan-
nel blockade, while producing a host of more compli-
cated biochemical and physiological effects. Mixing
drugs with such ‘indiscriminate’ actions as the estab-
lished anticonvulsants, will almost inevitably lead to
problems. The human brain is a delicate instrument,
and tampering with a range of neuronal properties may
have far-reaching consequences. In fact, considering
their potential for pharmacokinetic and pharmacody-
namic interactions, it is almost surprising that anyone
can tolerate polypharmacy with the older anticonvul-
sants!
It is fair to say that, with the advent of a new gen-
eration of anticonvulsants, polypharmacy appears to
be more promising. The newer AEDs have more pre-
dictable pharmacokinetics than the older agents45 and
the incidence and severity of pharmacokinetic interac-
tions with them is markedly reduced6, 45, which makes
their combination less hazardous and complicated11.
In addition, with the probable exceptions of topira-
mate and gabapentin, the new anticonvulsants are re-
puted to have a single, well-defined mode of action46.
While there is something appealing in the concept
of a pharmacological agent acting on a single pro-
cess to prevent seizures, some scepticism about the
assurances of specificity are warranted, given that af-
ter marketing, vigabatrin47, 48 and lamotrigine49 were
shown to have additional actions that may contribute
to their anticonvulsant effect. Further work on other
models has certainly hinted at other modes of action46,
and it should not surprise us if the number of ac-
tions of each drug increases with each different model
tested. Although careful investigation of the effect of
these new anticonvulsants might complicate our think-
ing about these compounds, it may in return open
up further therapeutic possibilities in the treatment of
epilepsy.
Despite these negative aspects of combinations of
the established AEDs, it is still rather puzzling that
the inevitability of AED polypharmacy has not in-
spired any large-scale clinical trials to ascertain which
combinations are most effective. In a series of stud-
ies in mice, Bourgeois and co-workers50–54 examined
the anticonvulsant and neurotoxic results of combining
the established anticonvulsants. Anticonvulsant con-
centrations were standardized to avoid the confound-
ing of the results by the expected pharmacokinetic in-
teractions. Using these methods, it was suggested that
combinations of phenytoin and valproic acid had an
anticonvulsant effect that was supra-additive (i.e. dis-
played synergism between the two drugs) while the
neurotoxic effects were merely additive45.
Further animal studies suggested that the anticon-
vulsant benefits of combining valproic acid with car-
bamazepine51 or ethosuximide52 outweighed the neu-
rotoxic effects, with similar positive effects from
a phenytoin/phenobarbital combination54. In con-
trast, a valproic acid/phenobarbital51 and phenobar-
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bital/carbamazepine54 combination were more disap-
pointing, with both the neurotoxic and anticonvulsant
effects being additive.
Of course, none of our patients are mice, so where
does this leave us? It may be considered surprising that
none of these potentially beneficial results were fol-
lowed up by proper clinical trials, although by the late
1980s, the newer anticonvulsants had begun to take
centre stage as the source of new hope for those with
intractable epilepsy.
For two decades there has been ongoing de-
bate about the relative merits of polypharmacy and
monotherapy. The fact that available monotherapies
are not perfect has left clinicians reliant on polyphar-
macy, and so doctors are left to choose between the
theoretically desirable and the practically unavoidable.
Given this situation, how can we best plan combina-
tion anticonvulsant drug therapy? This question can
only be addressed once several smaller problems have
been addressed.
How can we develop a rational plan for optimal
anticonvulsant polypharmacy?
(a) Chance observation
The history of epilepsy treatments is littered with
chance observations, from Hauptmann’s discovery of
the anticonvulsant effects of phenobarbital55 to the
discovery of the anticonvulsant properties of val-
proic acid56 and lamotrigine6. Serendipity is well-
recognized as a ‘method’ of formulating therapeu-
tic advances, being the pay-off for astute clinical
observation. Anecdotal reports have suggested spe-
cific benefit with particular combinations (e.g. viga-
batrin/lamotrigine57, lamotrigine/valproic acid58), but
none has been assessed in proper clinical trials.
One important point to note is that if clinical ob-
servation is to be relied upon to highlight ideal drug
combinations, then such opinions should be based on
better information. For example, it would be helpful
if the data upon which drug licensing applications are
based were made available at an early stage, preferably
in peer-reviewed journals. It has become apparent that
there is a paucity of freely available clinical and pre-
clinical data, even for those drugs on general release.
It is less than ideal that data regarding marketed com-
pounds have to be sifted from journal abstracts, and
it is probably unhealthy for our understanding of such
drugs to be based solely on the subjective (and occa-
sionally selective) data provided by the pharmaceuti-
cal industry.
(b) Meta-analysis
Meta-analyses comparing the newer drugs should be
interpreted with caution, as each has mostly succeeded
in comparing toxic doses of one compound with sub-
therapeutic doses of another. Other as yet untried
meta-analyses, however, are potentially far more pro-
ductive: prospective anticonvulsants have to undergo
clinical testing as add-on therapy, and one efficient
method of assessing drug combinations would be to
measure the relative benefits of each new treatment
in tandem with each established anticonvulsant. At
present, plans are underway to carry out such studies
[A. Marson, personal communication].
Comparison across trials should be interpreted with
great caution, but such analyses may help to highlight
any particularly potent combinations. The pharmaceu-
tical industry needs some encouragement to partici-
pate, since each company is understandably keen for
their product to be seen as a ‘cutting-edge’ compound
rather than as a cofactor. Such meta-analyses, how-
ever, are of great potential benefit to the industry, for
example in rapidly highlighting any potential impor-
tant adverse pharmacokinetic or pharmacodynamic in-
teractions.
(c) Systematic clinical trials involving each drug
combination
It would be ideal if every anticonvulsant combina-
tion could be tested in humans using rigorously de-
signed double-dummy, placebo-controlled studies59.
However, assuming that there are eight available an-
ticonvulsant compounds (a conservative estimate for
most countries), this allows 28 combinations of 2-drug
and 56 of 3-drug cotreatments60. Having four treat-
ment arms (two active monotherapies, one placebo,
one combination), such trials would require very large
numbers of patients, one-quarter of whom would be
receiving placebo.
In countries outside the USA at least, there is
some unease about giving placebo as monotherapy for
epilepsy, so in any future trials, common sense may
render the placebo arm unnecessary. It is (hopefully)
widely recognized that the new drugs are active an-
ticonvulsants, and it could be argued with equal con-
viction that placebo is not an adequate add-on treat-
ment for refractory epilepsy. The aim of any large trial
should not be to ‘reinvent the wheel’ and prove that a
combination is better than placebo, but to prove that
a particular combination is more beneficial than any
other. In an ideal world, with unlimited resources, and
an infinite supply of suitable patients, a placebo com-
parison may be reasonable, but since neither of these
conditions apply, direct comparison of anticonvulsants
combinations may have to suffice.
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One further way of limiting the number of patients
required would be to conduct trials only on preselected
combinations of drugs, i.e. those that have shown
particular promise in clinical practice (e.g. lamotrig-
ine/valproic acid61) or those that might, by virtue of
their neurochemical properties, seem to be well- suited
to combination (Table 1), e.g. vigabatrin/tiagabine,
gabapentin/ vigabatrin. It may be possible to predict
useful combinations using knowledge of neurophysi-
ology and neurobiochemistry.
Further limitation of the number of combinations
to be tested will be difficult. Some relatively basic
questions remain unanswered: should combined drugs
have similar (e.g. two GABAergic drugs or two glu-
tamatergic drugs) or different mechanism of action?
Limited studies in animal models62 have suggested
that a number of drugs acting on the same system may
be preferable, but much work has to be done to exam-
ine this fully. It could be argued that multiplicity of
action is what has traditionally bedevilled the use of
the older anticonvulsants: according to this view, we
should be moving away from drugs that have multiple
actions (‘intrinsic polypharmacy’) and searching for
a pharmacological action on a single system produc-
ing an anticonvulsant action. It is probably unrealistic
to expect that we will ever have such a drug, and in
any case it can be argued that drug combinations give
greater flexibility than a single drug with multiple ac-
tions, allowing adjustments to be made in the light of
any emergent adverse effects.
Characterizing ancillary actions of the
anticonvulsants—is it worth the effort?
To assist in the rational choice of drug combinations, it
is important to know not only the mechanism of action
of each drug, but what their biochemical ‘side effects’
are. Rational planning of anticonvulsant polyphar-
macy may begin by examining the effects of the new
anticonvulsants on the enzymes and substrates of the
GABA shunt in rodent cortex (Table 1). This raises
the possibility that combining two drugs that inhibit
GABA transaminase, vigabatrin and gabapentin, may
allow a fuller inhibition of this enzyme while mini-
mizing the inhibition of glutamic acid decarboxylase.
This may theoretically remove the ceiling to effective
dosage of vigabatrin71 or could even minimize any ad-
verse events72.
Knowledge of the AEDs’ biochemical effects may
also provide information on the combinations to avoid.
It would be interesting, for example, to assess the ef-
fect of a remacemide/vigabatrin combination on whole
brain GABA transaminase. Would this combination
have any efficacy in animal seizure models? Would a
dual depression of glutamic acid decarboxylase activ-
ity produce an even higher incidence of adverse ef-
fects? On suggesting theoretical advantages to some
combinations, the next step is to test each potential
combination in animal seizure models. Extrapolation
of animal effects, although not ideal, is done rou-
tinely in the introduction of novel anticonvulsant com-
pounds into early clinical trials. Even once a poten-
tially beneficial combination comes to our attention,
the assessment of any positive interaction will not be
easy.
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Fig. 1: Three isobolograms showing effects of combining
drugs with additive (A′), inhibitory (M′) and synergistic (S′)
effects.
How can we prove synergism in drug
combinations?
The isobologram outlined by Loewe in 195373, may
be the most effective way of proving synergism in
drug combinations (Fig. 1). Each point plotted on an
isobologram is an identical treatment effect (in Fig. 1,
this is taken as a 50% decrease in seizure frequency
{ED50} among a population). Administration of the
ED50 dose of either drug alone for the stated treat-
ment effect will, by definition, produce an identical
efficacy. Where drugs have additive effects, similar ef-
ficacy will be gained by partial replacement of one
drug with an equivalent amount of the other, produc-
ing a straight line of effect (A′). If the compounds in-
teract in an inhibitory manner, then addition of one
drug will require higher doses of the other to pro-
duce an identical effect, leading to a convex curve
plot (M′). In contrast, where the drugs act synergis-
tically, addition of one drug will allow a dispropor-
tionately greater reduction in the dose of the other
drug, leading to a concave curve (S′). In practice, the
isobologram has been used to assess (and disprove) the
presence of any potentiation between felbamate and
phenytoin73.
Where the isobologram would be unnecessary, of
Antiepileptic drugs: safety in numbers? 175
Table 1: Effect of various drugs on the enzymes and substrates of the GABA shunt.
Activity of Levels of
GAD GABA-T GABA Glutamate Glutamine
Vigabatrin62, 63 ↓↓ ↓↓ ↑↑ ↓↓ ↓↓
Gabapentin64, 65 ←→ ↓↓ ↑ ←→ ←→
Topiramate66, 67 ←→ ←→ ↑↑ ←→ ←→
Tiagabine62 ←→ ←→ ←→ ? ?
Levetiracetam68 ←→ ←→ ←→ ←→ ←→
Remacemide69 ↓ ↑ ←→ ↓ ←→
GABA-T = GABA-transaminase, GAD = Glutamic Acid Decarboxylase, ↓↓ = significant decrease, ↑↑ = significant increase,←→= No
effect, ↑ = increase of unknown significance, ? = unknown, ↓ = decrease of unknown significance.
course, would be where a drug, independent of any
pharmacokinetic interactions, acts on seizure models
only as part of a drug combination. This scenario
would in itself be an example of pharmacological syn-
ergy.
The number of potential anticonvulsant dose combi-
nations, and the huge number of subjects needed, may
hamper the use of isobolograms in clinical trials, but it
should not preclude their use in animal seizure models.
Use among animal seizure models would also over-
come the obstacle of defining ‘bioequivalence’ among
anticonvulsants. In a disease process as unpredictable
as epilepsy, it is almost impossible to specify, for ex-
ample, the dose of valproic acid that is ‘equivalent’ to
a particular dose of lamotrigine. In contrast to the clin-
ical setting, where there is a high degree of interindi-
vidual variation in pharmacokinetics and pharmacody-
namics of each AED, this is relatively easy to define
for a particular animal population.
To avoid this problem, any large-scale clinical trials
may require the standardization of the serum concen-
trations of anticonvulsants to ensure that patient are
undergoing comparable exposure to each drug. Frus-
tratingly, it should be pointed out that there is no proof
of a good correlation between serum concentrations
of most of the new anticonvulsants and their clinical
efficacy74.
What are the current gold-standard
anticonvulsant combinations?
At present, there is a lack of consensus on the re-
quirements for an adequate trial of anticonvulsant syn-
ergy. There have been a number of studies investigat-
ing the efficacy and tolerability of specific anticonvul-
sant combinations, but none is without design prob-
lems. There is currently an urgent need for pragmatic
clinical trials examining the benefits of combination
therapy. The lack of such trials may in itself be testi-
mony to our lack of understanding of the basic mech-
anisms of action of these drugs, an area where further
preclinical investigation may be vital.
In general, the principles of AED polypharmacy
should comply with the points made by Ferrendelli75.
Ideally, drugs used in combination should:
• have a high therapeutic index;
• not interact pharmacokinetically;
• have a low tendency to cause adverse events.
This helps us finally outline some of the anticonvul-
sant combinations that may be most promising in the
clinical arena.
• Lamotrigine and valproic acid
Some clinicians have observed that the combination
of lamotrigine and valproic acid has particular effi-
cacy, and this was originally thought to be the re-
sult of the well-documented inhibition of lamotrig-
ine metabolism caused by valproic acid6. Brodie et
al.58, as part of an open trial of add-on Lamotrig-
ine with withdrawal of the primary monotherapy,
showed a trend towards optimal benefit from a lam-
otrigine/valproic acid combination, even when lamot-
rigine concentrations were maintained after the with-
drawal of valproic acid. This was in contrast to the
findings in patients where the primary monother-
apy was carbamazepine or phenytoin, suggesting that
valproic acid and lamotrigine may interact syner-
gistically. Trials involving this combination will ne-
cessitate the provision of an unblinded observer to
ensure that plasma concentrations, of lamotrigine
in particular, are comparable between groups. The
suggestion that the combination exhibits synergism,
however, requires proof in a definitive double-blind
trial.
• Vigabatrin and gabapentin
Gabapentin is known to potentiate the effects of other
AEDs, even when their mode of action do not appear
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to be related. Vigabatrin and gabapentin inhibit GABA
transaminase and have different ancillary effects on
the GABA shunt (Table 1). For the reasons discussed
above, the combination of these two new anticonvul-
sants may theoretically have a higher efficacy and tol-
erability than either as monotherapy. Encouragingly,
both drugs have a wide therapeutic index, are free of
pharmacokinetic interactions, and are of proven bene-
fit in partial seizures6. Careful combination may prove
efficacious and well tolerated in the treatment of re-
fractory seizures.
CONCLUSION
Three decades of opposition to combining AEDs has
inhibited the desire to separate the good combinations
from the bad. Despite the introduction of new and ef-
fective AED monotherapies, polypharmacy with an-
ticonvulsants remains both inevitable and, for some,
beneficial. Remarkably there is still no definite clin-
ical evidence of synergism with anticonvulsants, or
even evidence that any particular combination is es-
pecially efficacious. For the last decade, it seems
that each international epilepsy meeting has featured
the obligatory lecture on combination therapy with
AEDs. In these 10 years, each time ideal combina-
tions are mentioned, the speaker (and it is usually
the same speaker!) provides a list of maybes, mights,
ifs and buts. In this age of evidence-based medicine,
hopefully we can all agree that this is no longer
enough. The increasing knowledge of the molecular
basis of epilepsy and its treatment should help the
search proceed more efficiently, but there is disap-
pointingly little will to push clinical research in this
direction.
Since the late 1960s there has been an enormous
investment of both time and money in developing a
number of new, effective, well-tolerated AEDs. While
none is a panacea for epilepsy, they are an undoubted
advance. It would be, to say the least, unfortunate if
we were to miss the opportunity to optimize their use.
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